Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on September 5, 2025, with the earliest event reported on that date. The filing details significant capital structure changes, including a proposed private offering of senior notes, the entry into a new credit facility, and potential debt redemptions. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbols HROW, HROWL, and HROWM.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period. However, it outlines the following capital structure metrics and proposed transactions:
- Proposed Offering: $250.0 million aggregate principal amount of senior unsecured notes due 2030 (2030 Notes).
- New Credit Facility: A commitment for up to $40.0 million in a senior secured revolving credit facility with Fifth Third Bank.
- Interest Rates (New Facility): Floating rate of Base Rate + 0.25% to 0.75% or SOFR + 1.25% to 1.75%, plus a 0.25% annual unused fee.
- Existing Debt to be Redeemed: 8.625% Senior Notes due 2026 (HROWL) and 11.875% Senior Notes due 2027 (HROWM).
- Existing Debt to be Repaid: Outstanding borrowings under the Oaktree Loan.
Material Changes and Proposed Transactions
The filing announces several material changes contingent upon the successful completion of the $250.0 million 2030 Notes Offering:
- Debt Refinancing: Proceeds from the Offering are intended to redeem the 2026 and 2027 Notes and prepay the Oaktree Loan.
- 2027 Notes Redemption: A conditional notice of full redemption was delivered for the 11.875% Senior Notes due 2027. If consummated, they will be redeemed on October 9, 2025, at 102% of principal plus accrued interest.
- 2026 Notes Redemption: The Company expects to redeem the 8.625% Senior Notes due 2026 at 100% of principal plus a make-whole amount and accrued interest.
- New Revolving Credit Facility: A $40.0 million facility is expected to close shortly after the Offering, secured by a first priority lien on substantially all assets.
- Acquisition Interest: On August 7, 2025, the Company entered a non-binding indication of interest to acquire the remaining ~55% of Melt Pharmaceuticals, Inc. (currently owning ~45%). The deal involves an initial cash payment of approximately $4.3 million plus contingent consideration based on FDA approval, reimbursement, and sales milestones.
Guidance, Risks, and Contingencies
Management commentary indicates that the proposed transactions are subject to significant conditions and risks:
- Offering Contingency: There is no assurance the $250.0 million Offering will be completed on favorable terms or at all. The redemption of the 2027 Notes is explicitly conditioned on the Offering generating at least $250.0 million in gross proceeds.
- Credit Facility Conditions: Closing of the new $40.0 million facility requires the Offering proceeds to reach at least $250.0 million and the repayment of outstanding indebtedness.
- Acquisition Uncertainty: The acquisition of Melt Pharmaceuticals is non-binding and subject to definitive agreements, diligence, and other conditions. No assurance is given regarding completion or timing.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as market conditions, negotiation failures, and execution risks that could cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the final terms and completion status of the $250.0 million 2030 Notes Offering.
- Confirm whether the conditional redemption of the 2027 Notes (due October 9, 2025) is executed based on Offering proceeds.
- Monitor the closing of the $40.0 million Fifth Third Bank revolving credit facility and its impact on liquidity.
- Track the progress of the non-binding acquisition of Melt Pharmaceuticals, Inc., specifically the negotiation of definitive agreements.
- Review the specific make-whole calculation for the 2026 Notes redemption to assess total debt exit costs.